These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 23826876

  • 1. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Sep; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 4. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M, EORTC Genitourinary Group.
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 10. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Jun; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 11. Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
    Sasaki T, Onishi T, Hoshina A.
    Endocr Relat Cancer; 2012 Oct; 19(5):725-30. PubMed ID: 22807499
    [Abstract] [Full Text] [Related]

  • 12. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y.
    Urol Int; 2005 Oct; 75(1):43-9. PubMed ID: 16037707
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE, Gabor Miklos GL.
    J Natl Cancer Inst; 2013 Oct 16; 105(20):1534-9. PubMed ID: 24092918
    [Abstract] [Full Text] [Related]

  • 14. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH, European Organisation for Research and Treatment of Cancer, Limburgs Universitair Centrum, AstraZeneca Pharmaceuticals.
    J Clin Oncol; 2005 Sep 01; 23(25):6139-48. PubMed ID: 16135480
    [Abstract] [Full Text] [Related]

  • 15. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W, Shang H, Pei X, Chen Y, Xie H, He D, Wang X, Li L.
    Int Urol Nephrol; 2017 Jan 01; 49(1):61-67. PubMed ID: 27837416
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 01; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 18. [Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer].
    Horiguchi A, Hatakeyama N, Ikeuchi K.
    Hinyokika Kiyo; 1999 Jan 15; 45(1):31-5. PubMed ID: 10086263
    [Abstract] [Full Text] [Related]

  • 19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 20. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.
    Prostate Cancer Prostatic Dis; 2012 Mar 15; 15(1):75-86. PubMed ID: 21986985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.